RHYTHM PHARMACEUTICLS ($RYTM) posted quarterly earnings results for Q4 2025 on Thursday, February 26th. The company reported earnings of -$0.73 per share, beating estimates of -$0.82 by $0.09. The company also reported revenue of $57,250,000, beating estimates of $57,162,768 by $87,232.
You can see Quiver Quantitative's $RYTM stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RHYTHM PHARMACEUTICLS Insider Trading Activity
RHYTHM PHARMACEUTICLS insiders have traded $RYTM stock on the open market 33 times in the past 6 months. Of those trades, 0 have been purchases and 33 have been sales.
Here’s a breakdown of recent trading of $RYTM stock by insiders over the last 6 months:
- JOSEPH SHULMAN (Chief Technical Officer) has made 0 purchases and 6 sales selling 43,781 shares for an estimated $4,831,490.
- PAMELA J. CRAMER (Chief Human Resources Officer) has made 0 purchases and 4 sales selling 29,566 shares for an estimated $2,987,425.
- HUNTER C SMITH (Chief Financial Officer) has made 0 purchases and 23 sales selling 21,653 shares for an estimated $2,217,133.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
RHYTHM PHARMACEUTICLS Hedge Fund Activity
We have seen 154 institutional investors add shares of RHYTHM PHARMACEUTICLS stock to their portfolio, and 144 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- VANGUARD GROUP INC added 1,214,489 shares (+24.3%) to their portfolio in Q4 2025, for an estimated $129,998,902
- UBS AM, A DISTINCT BUSINESS UNIT OF UBS ASSET MANAGEMENT AMERICAS LLC removed 1,200,868 shares (-68.6%) from their portfolio in Q4 2025, for an estimated $128,540,910
- ALKEON CAPITAL MANAGEMENT LLC removed 1,017,700 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $108,934,608
- RA CAPITAL MANAGEMENT, L.P. added 985,478 shares (+17.3%) to their portfolio in Q4 2025, for an estimated $105,485,565
- PRIMECAP MANAGEMENT CO/CA/ removed 784,190 shares (-18.4%) from their portfolio in Q4 2025, for an estimated $83,939,697
- JENNISON ASSOCIATES LLC added 507,017 shares (+123.2%) to their portfolio in Q4 2025, for an estimated $54,271,099
- ROCKEFELLER CAPITAL MANAGEMENT L.P. added 444,029 shares (+5007.1%) to their portfolio in Q4 2025, for an estimated $47,528,864
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
RHYTHM PHARMACEUTICLS Analyst Ratings
Wall Street analysts have issued reports on $RYTM in the last several months. We have seen 9 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 01/20/2026
- Guggenheim issued a "Buy" rating on 12/17/2025
- Citizens issued a "Market Outperform" rating on 12/12/2025
- Needham issued a "Buy" rating on 12/11/2025
- Citigroup issued a "Buy" rating on 11/25/2025
- Canaccord Genuity issued a "Buy" rating on 11/10/2025
- Goldman Sachs issued a "Buy" rating on 10/17/2025
To track analyst ratings and price targets for RHYTHM PHARMACEUTICLS, check out Quiver Quantitative's $RYTM forecast page.
RHYTHM PHARMACEUTICLS Price Targets
Multiple analysts have issued price targets for $RYTM recently. We have seen 11 analysts offer price targets for $RYTM in the last 6 months, with a median target of $142.0.
Here are some recent targets:
- Lisa Walter from RBC Capital set a target price of $145.0 on 02/19/2026
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $125.0 on 01/20/2026
- Derek Archila from Wells Fargo set a target price of $145.0 on 01/20/2026
- Joseph Stringer from Needham set a target price of $148.0 on 01/09/2026
- Seamus Fernandez from Guggenheim set a target price of $140.0 on 12/17/2025
- Corinne Jenkins from Goldman Sachs set a target price of $157.0 on 12/12/2025
- Whitney Ijem from Canaccord Genuity set a target price of $141.0 on 12/12/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
